New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2013
09:05 EDTAMBIAmbit Biosciences upgraded to Outperform from Market Perform at BMO Capital
BMO Capital upgraded Ambit following the announcement that the FDA has agreed to a dosing regimen for its Phase III study of quizartinib in patients with FLT3-ITD+ AML. Price target raised to $14 from $10.
News For AMBI From The Last 14 Days
Check below for free stories on AMBI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AMBI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use